Category

Latest News
Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria, Sanofi SA, and the Stop TB Partnership is pleased to announce a significant reduction in the price of rifapentine (Priftin®) manufactured by Sanofi SA. Read more here
Read More
Press Release Pricing Agreement Makes TB Prevention Affordable for High-Burden, Low-, Lower-Middle and Upper-Middle Income Countries Aurum Institute on behalf of the IMPAACT4TB project congratulates Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria and Sanofi for having reached a volume-based agreement, securing a significant price discount for rifapentine (Priftin®) Hyderabad (31 October 2019)—A...
Read More
The IMPAACT4TB Consortium will be hosting a Satellite Session at the Union Conference as an introduction to a Short Course Prevention Therapy, 3HP. Looking forward to seeing you there!  
Read More
The latest WHO Global TB report  2019 was published on 20 October 2019 and has been every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in the prevention, diagnosis and treatment of the disease, at global, regional and country...
Read More
TAG, our Consortium Partner has launched the Pediatric Tuberculosis (TB) section of their  2019 Pipeline Report. This section provides an overview of the research and development of innovations for diagnosing, preventing, treating TB in children. You can now read online and download  Paediatric TB Diagnosis, Prevention, and Treatment by Lindsay McKenna
Read More
No #EndAIDS without #EndTB From 20-24 July 2019, members of the IMPAACT4TB Consortium were in Mexico City, where they joined hundreds of other delegates in discussing the links between HIV and TB, and the implications of TB prevention for people living with HIV.
Read More
#IAS2019 Social Media Toolkit Below, you will find social media content to be used to raise awareness of the need to prevent TB in order to end TB, especially among people living with HIV. The content also includes information about a recent study showing that a short regimen for preventing TB (3HP) has been found...
Read More
Short Regimen for Preventing TB Found Safe When Co-administered with New First-line HIV Drug New study paves the way for scale-up of TB prevention among people living with HIV, who are dying from TB in large numbers SEATTLE (6 March 2019)—In an important moment for tuberculosis (TB) control, a new study finds that a shorter...
Read More
Approximately, 1.7 billion individuals were latently infected with tuberculosis in 2014, just under a quarter of the global population. Among the latently infected population, people living with HIV and children under 5 who are household contacts of bacteriologically-confirmed pulmonary TB cases, are at a higher risk of progressing from latent infection to active disease. In...
Read More
When it comes to preventing TB, we can and must do better Statement by Gavin Churchyard, CEO of Aurum Institute We’ve known how to prevent and treat TB for over 70 years. Yet, in 2017 an estimated 10 million people fell ill from the disease, and every day more than 4,000 people die from TB....
Read More
1 2 3 4